To determine the influence of pre-interventionally existing portal vein thrombosis on the ablation success of percutaneous tumor ablation of HCC.
MATERIALS AND METHODS:
15 patients with HCC and pre-existing portal vein thrombosis underwent thermal tumor ablation. We retrospectively analyzed the pre- and post-interventionally performed CT and MRI scans in terms of technical success as well as the complication rate. The portal vein thrombosis was classified into segmental, lobar and central thrombus.
RESULTS:
In 13/15 cases (87%) complete ablation with no evidence of residual tumor tissue was seen 6 weeks after the procedure in contrast-enhanced MRI scans and contrast-enhanced ultrasound (CEUS). No major and 2 minor complications were observed after the ablation procedure.
CONCLUSION:
Reduced perfusion due to pre-interventionally existing portal vein thrombosis has no significant impact on the ablation success or the complication rate.
ParkJ.-W., ChenM., ColomboM., RobertsL.R., SchwartzM., ChenP.-J., KudoM., JohnsonP., WagnerS., OrsiniL.S. and ShermanM., Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study, Liver Int35 (2015), 2155–2166.
2.
El-SeragH.B., Hepatocellular Carcinoma, N Engl J Med365 (2011), 1118–1127.
3.
OgrenM., BergqvistD., BjörckM., AcostaS., ErikssonH. and SternbyN.H., Portal vein thrombosis: Prevalence, patient characteristics and lifetime risk: A population study based on 23,796 consecutive autopsies, World J Gastroenterol12 (2006), 2115–2119.
4.
TakizawaD., KakizakiS., SoharaN., SatoK., TakagiH., AraiH., KatakaiK., KojimaA., MatsuzakiY. and MoriM., Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Clinical Characteristics, Prognosis, and Patient Survival Analysis, Dig Dis Sci52 (2007), 3290–3295.
5.
PirisiM., AvelliniC., FabrisC., ScottC., BardusP., SoardoG., BeltramiC.A. and BartoliE., Portal vein thrombosis in hepatocellular carcinoma: Age and sex distribution in an autopsy study, J Cancer Res Clin Oncol124 (1998), 397–400.
6.
TarantinoL., AmbrosinoP. and Di MinnoM.N.D., Contrast-enhanced ultrasound in differentiating malignant from benign portal vein thrombosis in hepatocellular carcinoma, World J Gastroenterol21 (2015), 9457–9460.
7.
AhnJ.-H., YuJ.-S., ChoE.-S., ChungJ.-J., KimJ.H. and KimK.W., Diffusion-weighted MRI of malignant versus benign portal vein thrombosis, Korean J Radiol17 (2016), 533–540.
8.
LivraghiT., GrigioniW., MazziottiA., SangalliG. and VettoriC., Percutaneous alcohol injection of portal thrombosis in hepatocellular carcinoma: A new possible treatment, Tumori76 (1990), 394–397.
9.
ChenX.-P., QiuF.-Z., WuZ.-D., ZhangZ.-W., HuangZ.-Y., ChenY.-F., ZhangB.-X., HeS.-Q. and ZhangW.-G., Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma, Ann Surg Oncol13 (2006), 940–946.
10.
ChengS., WuM., ChenH., ShenF., YangJ., CongW., WangP. and ZhaoY., Significance of typing of tumor thrombi in determination of treatment and assessment of prognosis of hepatocellular carcinoma with tumor thrombi in the portal vein, Zhonghua Yi Xue Za Zhi84 (2004), 3–5.
11.
Ethical guidelines for publication in Clinical Hemorheology and Microcirculation: Update 2016, Clin Hemorheol Microcirc63 (2016), 1–2.
12.
LubnerM.G., BraceC.L., HinshawJ.L. and LeeF.T., Microwave tumor ablation: Mechanism of action, clinical results, and devices, J Vasc Interv Radiol21 (2010), S192–S203.
13.
CurleyS.A., IzzoF., DelrioP., EllisL.M., GranchiJ., ValloneP., FioreF., PignataS., DanieleB. and CremonaF., Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: Results in 123 patients, Ann Surg230 (1999), 1–8.
14.
HammB., StaksT., MühlerA., BollowM., TaupitzM., FrenzelT., WolfK.J., WeinmannH.J. and LangeL., Phase I clinical evaluation of Gd-EOB-DTPA as a hepatobiliary MR contrast agent: Safety, pharmacokinetics, and MR imaging, Radiology195 (1995), 785–792.
15.
OmaryR.A., BettmannM.A., CardellaJ.F., BakalC.W., SchwartzbergM.S., SacksD., RhollK.S., MeranzeS.G. and LewisC.A., Society of Interventional Radiology Standards of Practice Committee, Quality improvement guidelines for the reporting and archiving of interventional radiology procedures, J Vasc Interv Radiol14 (2003), S293–S295.
16.
GeorgiadesC.S., HongK., D’AngeloM. and GeschwindJ.-F.H., Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis, J Vasc Interv Radiol16 (2005), 1653–1659.
17.
KulikL.M., CarrB.I., MulcahyM.F., LewandowskiR.J., AtassiB., RyuR.K., SatoK.T., BensonA., NemcekA.A., GatesV.L., AbecassisM., OmaryR.A. and SalemR., Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis, Hepatology47 (2007), 71–81.
18.
MinagawaM., MakuuchiM., TakayamaT. and OhtomoK., Selection criteria for hepatectomy in patients with hepatocellular carcinoma and portal vein tumor thrombus, Ann Surg233 (2001), 379–384.
19.
ShiJ., LaiE.C.H., LiN., GuoW.-X., XueJ., LauW.Y., WuM.-C. and ChengS.-Q., Surgical treatment of hepatocellular carcinoma with portal vein tumor thrombus, Ann Surg Oncol17 (2010), 2073–2080.
20.
TateishiR., ShiinaS., TerataniT., ObiS., SatoS., KoikeY., FujishimaT., YoshidaH., KawabeT. and OmataM., Percutaneous radiofrequency ablation for hepatocellular carcinoma, Cancer103 (2005), 1201–1209.
21.
HowensteinM.J. and SatoK.T., Complications of radiofrequency ablation of hepatic, pulmonary, and renal neoplasms, Semin Intervent Radiol27 (2010), 285–295.
22.
MulierS., MulierP., NiY., MiaoY., DupasB., MarchalG., De WeverI. and MichelL., Complications of radiofrequency coagulation of liver tumours, Br J Surg89 (2002), 1206–1222.
23.
LivraghiT., SolbiatiL., MeloniM.F., GazelleG.S., HalpernE.F. and GoldbergS.N., Treatment of focal liver tumors with percutaneous radio-frequency ablation: Complications encountered in a multicenter study, Radiology226 (2003), 441–451.
